{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:20:07Z","timestamp":1785943207334,"version":"3.56.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide decision-focused estimates of the benefit of perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer using Bayesian modeling of reconstructed individual patient data (rIPD) from the phase 3 NIAGARA trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Individual patient data were reconstructed from published Kaplan\u2013Meier curves and event counts (durvalumab, n\u00a0=\u00a0533; control, n\u00a0=\u00a0530). Bayesian piecewise-exponential models with prespecified intervals (0\u201312, 12\u201324, 24\u201336, and 36\u201360\u00a0months) were used to estimate interval-specific hazards, posterior probabilities of benefit, absolute survival differences, number needed to treat (NNT), and restricted mean survival time (RMST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For event-free survival (EFS), the overall hazard ratio (HR) was 0.68 (95% credible interval [CrI], 0.56\u20130.82). The absolute improvement in EFS with durvalumab was 6.3%, 8.5%, and 10.8% at 12, 24, and 36\u00a0months, respectively, corresponding to median NNT values of 15.8, 11.7, and 9.2. The gain in RMST for EFS was 2.48\u00a0months over 36\u00a0months and 5.98\u00a0months over 60\u00a0months. For overall survival (OS), the overall HR was 0.74 (95% CrI, 0.59\u20130.93). The absolute improvement in OS was 2.7%, 7.3%, and 7.5% at 12, 24, and 36\u00a0months, respectively, with a median NNT of 13.8 at 24\u00a0months. The gain in RMST for OS was 1.66\u00a0months over 36\u00a0months and 3.31\u00a0months over 60\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This Bayesian rIPD reanalysis complements the primary NIAGARA report by translating relative effects into clinically meaningful absolute benefits over prespecified perioperative time points, supporting perioperative counseling and institutional decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag072","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:42:50Z","timestamp":1776253370000},"page":"1015-1021","source":"Crossref","is-referenced-by-count":0,"title":["Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-7071","authenticated-orcid":false,"given":"Kohei","family":"Hirose","sequence":"first","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]},{"name":"Department of Urology, Zigong Fourth People\u2019s Hospital , No. 19 Tanmulin Street, Ziliujing District, Zigong, Sichuan 643000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-3345","authenticated-orcid":false,"given":"Motohiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Hospital , Mizonokuchi, 5-1-1 Futago, Takatsu-ku, Kawasaki, Kanagawa 213-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-1580","authenticated-orcid":false,"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026080510415367400_ref1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080510415367400_ref2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet."},{"key":"2026080510415367400_ref3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026080510415367400_ref4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2026080510415367400_ref5","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1093\/bioinformatics\/btn536","article-title":"Reconstructing tumor-wise protein expression in tissue microarray studies using a Bayesian cell mixture model","volume":"24","author":"Shen","year":"2008","journal-title":"Bioinformatics."},{"key":"2026080510415367400_ref6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pst.2256","article-title":"A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint","volume":"22","author":"Qing","year":"2023","journal-title":"Pharm Stat"},{"key":"2026080510415367400_ref7","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ."},{"key":"2026080510415367400_ref8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers","volume":"23","author":"Han","year":"2022","journal-title":"Korean J Radiol"},{"key":"2026080510415367400_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/0470092602","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"Spiegelhalter","year":"2004"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/1015\/68186180\/hyag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/1015\/68186180\/hyag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:41:57Z","timestamp":1785940917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/8\/1015\/8664825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag072","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,29]]}}}